MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Charles River Laboratories International Total Shareholders Equity 2011-2025 | CRL
Annual Total Shareholders Equity Charles River Laboratories International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.46 B | 3.6 B | 2.98 B | 2.54 B | 2.12 B | 1.63 B | 1.32 B | 1.05 B | 837 M | 733 M | 672 M | 641 M | 601 M | 526 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.6 B | 526 M | 1.62 B |
Quarterly Total Shareholders Equity Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.41 B | 3.35 B | 3.19 B | 3.46 B | 3.79 B | 3.73 B | 3.65 B | 3.6 B | 3.31 B | 3.26 B | 3.11 B | 2.98 B | 2.63 B | 2.65 B | 2.61 B | 2.53 B | 2.43 B | 2.32 B | 2.18 B | 2.11 B | 2.11 B | 2.11 B | 2.11 B | 1.63 B | 1.63 B | 1.63 B | 1.63 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B | 1.05 B | 1.05 B | 1.05 B | 1.05 B | 837 M | 837 M | 837 M | 837 M | 733 M | 733 M | 733 M | 733 M | 672 M | 672 M | 672 M | 672 M | 641 M | 641 M | 641 M | 641 M | 601 M | 601 M | 601 M | 601 M | 526 M | 526 M | 526 M | 526 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.79 B | 526 M | 1.67 B |
Total Shareholders Equity of other stocks in the Diagnostics research industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-48.2 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
27.5 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
19.6 M | $ 19.33 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 20.97 | -1.38 % | $ 226 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
86 M | $ 0.23 | -4.4 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 39.53 | -1.4 % | $ 1.1 B | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.52 | - | $ 1.93 M | USA |
 |
DarioHealth Corp.
DRIO
|
58.1 M | $ 10.17 | 1.29 % | $ 289 M | Israel |
 |
DexCom
DXCM
|
2.07 B | $ 67.51 | 0.13 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
49.5 B | $ 230.0 | -0.45 % | $ 168 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 101.56 | 0.02 % | $ 18.8 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 26.78 | -0.85 % | $ 810 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.69 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 19.47 | -1.32 % | $ 1.05 B | USA |
 |
Celcuity
CELC
|
116 M | $ 101.9 | -0.7 % | $ 4.02 B | USA |
 |
Anixa Biosciences
ANIX
|
20 M | $ 3.21 | -6.25 % | $ 102 K | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 226.52 | 0.26 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-140 M | $ 103.35 | 0.94 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
701 M | $ 6.44 | -1.68 % | $ 583 M | USA |
 |
Illumina
ILMN
|
2.37 B | $ 135.12 | -0.15 % | $ 21.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.56 M | $ 4.94 | -3.14 % | $ 2.65 M | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 7.12 | -0.35 % | $ 1.54 B | USA |
 |
National Research Corporation
NRC
|
49 M | $ 18.74 | 0.46 % | $ 460 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.78 B | $ 176.16 | 0.15 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 6.76 | -0.88 % | $ 877 M | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
8.05 B | $ 254.32 | 0.02 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 182.75 | -0.51 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.6 B | $ 688.22 | 0.01 % | $ 56.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
701 M | $ 1.77 | -5.85 % | $ 449 M | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 66.73 | 0.07 % | $ 4.62 B | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 419.64 | 0.11 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
5.39 B | $ 138.31 | 0.03 % | $ 42 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.7 | 1.9 % | $ 6.2 M | USA |
 |
Bioventus
BVS
|
174 M | $ 7.4 | 0.27 % | $ 464 M | USA |
 |
NeoGenomics
NEO
|
902 M | $ 12.33 | 0.2 % | $ 1.56 B | USA |